[et_pb_section fb_built=”1″ next_background_color=”#f4f4f4″ admin_label=”Why Choose Us Section” _builder_version=”3.22.7″ background_color=”#40ef92″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(55,200,171,0.6)” background_color_gradient_end=”#40ef92″ background_color_gradient_direction=”212deg” background_color_gradient_overlays_image=”on” background_image=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/fondo-futuro.jpg” custom_padding=”110px|0px|110px|0px” bottom_divider_style=”ramp2″][et_pb_row custom_padding=”|||” _builder_version=”3.22.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”1400px” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_text _builder_version=”3.22.7″ text_font=”||||||||” header_font=”|700|||||||” header_text_align=”center” header_text_color=”#ffffff” header_font_size=”50px” header_3_font=”|700|||||||” header_3_text_align=”center” header_3_text_color=”#ffffff” header_3_font_size=”32px” text_orientation=”center”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_line_height=”1.8em” header_font=”||||||||” text_orientation=”center” background_layout=”dark”]<\/p>\n
Limnopharma technology<\/strong> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ next_background_color=”#e2e2e2″ admin_label=”Classes Section” _builder_version=”3.22.7″ background_color=”#f4f4f4″ custom_padding=”110px|0px|100px|0px||” bottom_divider_style=”arrow3″ bottom_divider_height=”75px”][et_pb_row custom_padding=”|40px||40px” custom_margin=”|auto|0px|auto||” admin_label=”Class” _builder_version=”3.22.7″ background_color=”#ffffff” border_radii=”on|6px|6px|6px|6px” box_shadow_style=”preset1″ box_shadow_vertical=”10px” box_shadow_blur=”24px” box_shadow_spread=”6px” box_shadow_color=”rgba(0,0,0,0.06)”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_divider divider_position=”center” divider_weight=”5px” _builder_version=”3.22.7″ width=”60px” custom_margin=”||0px” custom_padding=”||0px”][\/et_pb_divider][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_text_color=”#486066″ text_font_size=”15px” text_line_height=”1.8em” header_3_font=”|700|||||||” header_3_text_color=”#486066″ header_3_font_size=”18px” header_3_line_height=”1.4em” z_index_tablet=”500″ locked=”off”]<\/p>\n Limnopharma<\/strong> develops natural phenolic derivatives, which combine neuroprotective and anti-inflammatory effects. The LIM21 and LIM109 molecules are the result of the optimization, in successive stages, of a family of 75 compounds.<\/p>\n In the first screening, the 18 candidates showing the best results during in vitro neuroprotection and inflammation experiments were selected.<\/p>\n Then, the 18 selected candidates were subjected to experiments in vivo using the zebrafish model to reassess neuroprotection and toxicity, resulting in 7 “finalist” compounds. With these compounds, AMD and RP trials in animal models (mice) were conducted.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”3.22.7″ header_font=”||||||||” header_3_font=”|600|||||||” header_3_text_align=”center” header_3_text_color=”#000000″]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_margin=”||60px” _builder_version=”3.22.7″ background_color=”#ffffff” box_shadow_style=”preset3″ box_shadow_vertical=”10px” box_shadow_blur=”14px” box_shadow_spread=”-7px”][et_pb_column type=”1_3″ _builder_version=”3.0.47″][et_pb_image src=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/ojo-sano.png” align=”center” _builder_version=”3.22.7″ width=”75%”][\/et_pb_image][et_pb_text _builder_version=”3.22.7″ header_font=”||||||||” header_3_font=”|600|||||||” header_3_text_align=”center” header_3_text_color=”#000000″]<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”3.0.47″][et_pb_image src=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/ojo-enfermo.png” align=”center” _builder_version=”3.22.7″ width=”75%”][\/et_pb_image][et_pb_text _builder_version=”3.22.7″ header_font=”||||||||” header_3_font=”|600|||||||” header_3_text_align=”center” header_3_text_color=”#000000″]<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”3.0.47″][et_pb_image src=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/ojo-tratado.png” align=”center” _builder_version=”3.22.7″ width=”75%”][\/et_pb_image][et_pb_text _builder_version=”3.22.7″ header_3_font=”|600|||||||” header_3_text_align=”center” header_3_text_color=”#000000″ z_index_tablet=”500″]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding=”|40px||40px” custom_margin=”||60px|” admin_label=”Class” _builder_version=”3.22.7″ background_color=”#ffffff” border_radii=”on|6px|6px|6px|6px” box_shadow_style=”preset1″ box_shadow_vertical=”10px” box_shadow_blur=”24px” box_shadow_spread=”6px” box_shadow_color=”rgba(0,0,0,0.06)”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_divider divider_position=”center” divider_weight=”5px” _builder_version=”3.22.7″ width=”60px” custom_margin=”||0px” custom_padding=”||0px”][\/et_pb_divider][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_text_color=”#486066″ text_font_size=”15px” text_line_height=”1.8em” header_font=”||||||||” header_3_font=”|700|||||||” header_3_text_color=”#486066″ header_3_font_size=”18px” header_3_line_height=”1.4em” locked=”off”]<\/p>\n The compounds studied are protected by two patents the worldwide rights to which are the exclusive property of Limnopharma<\/strong>.<\/p>\n Limnopharma<\/strong> has recently entered the national phases of applications for both patents. There is freedom to operate in relation to existing related medications.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding=”|40px||40px” custom_margin=”||60px|” admin_label=”Class” _builder_version=”3.22.7″ background_color=”#ffffff” border_radii=”on|6px|6px|6px|6px” box_shadow_style=”preset1″ box_shadow_vertical=”10px” box_shadow_blur=”24px” box_shadow_spread=”6px” box_shadow_color=”rgba(0,0,0,0.06)”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_divider divider_position=”center” divider_weight=”5px” _builder_version=”3.22.7″ width=”60px” custom_margin=”||0px” custom_padding=”||0px”][\/et_pb_divider][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_text_color=”#486066″ text_font_size=”15px” text_line_height=”1.8em” header_3_font=”|700|||||||” header_3_text_color=”#486066″ header_3_font_size=”18px” header_3_line_height=”1.4em” z_index_tablet=”500″ locked=”off”]<\/p>\n Why do we think it is worth endorsing our treatments? Our compounds have proven effective in the treatment of both RP and dry AMD in animal models, when administered by subretinal injection and in eye drop form.<\/p>\n This opens up the possibility of developing topical treatments (such as eye drops or ointment), which could, in turn, foster their long-term viability as non-aggressive or invasive forms of treatment administration in patients and therefore with little or no risk to the eye.<\/p>\n Additionally, in contrast to most molecules currently tested in clinical trials – based on gene therapy or biological molecules -, the compounds proposed by Limnopharma<\/strong> are small and derive from natural products similar to traditional drugs.<\/p>\n It is important to remember that there is currently no treatment for either dry AMD patients or the vast majority of RP patients. Therefore, for approximately 180 million people in the world, the treatment offered by Limnopharma<\/strong> would be the only one available.<\/p>\n [\/et_pb_text][et_pb_image src=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/inyeccion-vs-gotas-1.jpg” align=”center” _builder_version=”3.22.7″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding=”|40px||40px” custom_margin=”||60px|” admin_label=”Class” _builder_version=”3.22.7″ background_color=”#ffffff” border_radii=”on|6px|6px|6px|6px” box_shadow_style=”preset1″ box_shadow_vertical=”10px” box_shadow_blur=”24px” box_shadow_spread=”6px” box_shadow_color=”rgba(0,0,0,0.06)”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_divider divider_position=”center” divider_weight=”5px” _builder_version=”3.22.7″ width=”60px” custom_margin=”||0px” custom_padding=”||0px”][\/et_pb_divider][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_text_color=”#486066″ text_font_size=”15px” text_line_height=”1.8em” header_3_font=”|700|||||||” header_3_text_color=”#486066″ header_3_font_size=”18px” header_3_line_height=”1.4em” z_index_tablet=”500″ locked=”off”]<\/p>\n The company will follow a highly virtual business model, outsourcing most validation and manufacturing activities to expedite the development of its first products and reduce capital requirements. Given the magnitude of the initial investment required, the sources of financing will come from more or less specialized private investment funds, as well as public investment and subsidies.<\/p>\n Limnopharma’s<\/strong> main objectives are:<\/p>\n At this validation point, Limnopharma<\/strong> will seek opportunities to partially or totally sub-license the rights to the development and marketing of its products to large multinational pharmaceutical companies with a significant presence in the ophthalmology market.<\/p>\n In this way, it will take advantage of its experience and capacity in clinical trials, regulatory approval and manufacturing, as well as its distribution networks to introduce the product on the market, etc. The company’s revenue stream will consist of sub-license fees, payments by development, regulatory and marketing milestones, and ongoing royalties from drug sales.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22.7″ background_color=”#e2e2e2″ background_blend=”overlay” custom_padding=”50px||50px|||” z_index_tablet=”500″ global_module=”223″][et_pb_row _builder_version=”3.22.7″ max_width=”1100px”][et_pb_column type=”1_2″ _builder_version=”3.0.47″][et_pb_image src=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/footer-logo.png” _builder_version=”3.22.7″ width=”40%”][\/et_pb_image][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_text_color=”#8c8c8c” text_line_height=”1.8em” z_index_tablet=”500″]<\/p>\n New therapies for retinal diseases. [\/et_pb_text][et_pb_social_media_follow _builder_version=”3.22.7″ border_radii=”on|25px|25px|25px|25px”][et_pb_social_media_follow_network social_network=”facebook” _builder_version=”3.22.7″ background_color=”#8c8c8c” follow_button=”off” url_new_window=”on”]facebook[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”twitter” _builder_version=”3.22.7″ background_color=”#8c8c8c” follow_button=”off” url_new_window=”on”]twitter[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”linkedin” _builder_version=”3.22.7″ background_color=”#8c8c8c” border_radii=”on|25px|25px|25px|25px” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.0.47″][et_pb_text _builder_version=”3.22.7″ header_text_align=”center” header_3_text_align=”left” header_3_font_size=”29px” header_4_font=”|600|||||||” header_4_text_align=”left” header_4_text_color=”#2d2d2d” text_orientation=”center” z_index_tablet=”500″]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”3.22.7″ text_font=”||||||||” text_text_color=”#8c8c8c”]<\/p>\n Avda. de la Innovaci\u00f3n, 1 [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”3.0.47″][et_pb_text _builder_version=”3.22.7″ header_text_align=”center” header_3_text_align=”left” header_3_font_size=”29px” header_4_font=”|600|||||||” header_4_text_align=”left” header_4_text_color=”#2d2d2d” text_orientation=”center” z_index_tablet=”500″]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”3.22.7″ text_text_color=”#8c8c8c” z_index_tablet=”500″]<\/p>\n \u00b7 About us<\/a> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" [et_pb_section fb_built=”1″ next_background_color=”#f4f4f4″ admin_label=”Why Choose Us Section” _builder_version=”3.22.7″ background_color=”#40ef92″ use_background_color_gradient=”on” background_color_gradient_start=”rgba(55,200,171,0.6)” background_color_gradient_end=”#40ef92″ background_color_gradient_direction=”212deg” background_color_gradient_overlays_image=”on” background_image=”https:\/\/limnopharma.com\/en\/wp-content\/uploads\/sites\/4\/fondo-futuro.jpg” custom_padding=”110px|0px|110px|0px” bottom_divider_style=”ramp2″][et_pb_row custom_padding=”|||” _builder_version=”3.22.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”1400px” locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_text _builder_version=”3.22.7″ text_font=”||||||||” header_font=”|700|||||||” header_text_align=”center” header_text_color=”#ffffff” header_font_size=”50px” header_3_font=”|700|||||||” header_3_text_align=”center” header_3_text_color=”#ffffff” header_3_font_size=”32px” text_orientation=”center”] The solution [\/et_pb_text][et_pb_text _builder_version=”3.22.7″ text_font=”Open Sans||||||||” text_line_height=”1.8em” header_font=”||||||||” text_orientation=”center” background_layout=”dark”] Limnopharma technologyLIM21 and LIM109 molecules [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ next_background_color=”#e2e2e2″ […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":""},"_links":{"self":[{"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/pages\/12"}],"collection":[{"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/comments?post=12"}],"version-history":[{"count":36,"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/pages\/12\/revisions"}],"predecessor-version":[{"id":522,"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/pages\/12\/revisions\/522"}],"wp:attachment":[{"href":"https:\/\/limnopharma.com\/en\/wp-json\/wp\/v2\/media?parent=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
LIM21 and LIM109 molecules<\/strong><\/p>\nOur compounds<\/h3>\n
Retinitis Pigmentosa: background image of mouse eye<\/h3>\n
Healthy eye<\/h3>\n
Sick eye<\/h3>\n
Sick eye treated with LIM21<\/h3>\n
Intellectual property<\/h3>\n
Treatments<\/h3>\n
Our business model<\/h3>\n
\n
\nTreatments for Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)<\/p>\nHeadquarters<\/h4>\n
\nEdificio BIC
\n18016 – Granada<\/p>\nLinks of interest<\/h4>\n
\u00b7 The problem<\/a>
\u00b7 The solution<\/a>
\u00b7 Inversores
\u00b7 Contacto<\/p>\n